A single-centre, open-label, randomised, two-stage Phase I study of Chiglitazar in Healthy Chinese Volunteers
Latest Information Update: 08 May 2019
At a glance
- Drugs Chiglitazar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chipscreen Biosciences
- 08 May 2019 New trial record
- 29 Apr 2019 Results published in the Clinical Drug Investigation